In vitro potential of equine DEFA1 and eCATH1 as alternative antimicrobial drugs in rhodococcosis Treatment

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 1749-1755

  Schlusselhuber, Margot ^a   Jung, Sascha ^b   Bruhn, Oliver ^c   Goux, Didier ^d   Leippe, Matthias ^b   Leclercq, Roland ^e   Laugier, Claire ^a   Grötzinger, Joachim ^b   Cauchard, Julien ^a  

^a FRENCH AGENCY FOR FOOD   (France)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITÉ DE CAEN   (France)

^e UNIVERSITÉ DE CAEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN 1; CATHELICIDIN 1; ERYTHROMYCIN; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL MEMBRANE; CIRCULAR DICHROISM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOLYSIS; DRUG CYTOTOXICITY; FEMALE; GROWTH INHIBITION; HORSE; IN VITRO STUDY; INFECTION CONTROL; MAMMAL CELL; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; RHODOCOCCOSIS; RHODOCOCCUS EQUI; STREPTOCOCCUS EQUI ZOOEPIDEMICUS;

ACTINOMYCETALES INFECTIONS; ALPHA-DEFENSINS; ANIMALS; ANTI-BACTERIAL AGENTS; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; CIRCULAR DICHROISM; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; FEMALE; HEMOLYSIS; HORSE DISEASES; HORSES; LIPOSOMES; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; PHOSPHOLIPIDS; RHODOCOCCUS EQUI; SALT-TOLERANCE; SHEEP; VERO CELLS;

EID: 84858640283     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05797-11     Document Type: Article

References (49)

1. Anonymous. 1992. Synergism testing: broth microdilution checkerboard and broth macrodilution methods. American Society for Microbiology, Washington, DC.
2. Asoh N, et al. 2003. Emergence of rifampin-resistant Rhodococcus equi with several types of mutations in the rpoB gene among AIDS patients in northern Thailand. J. Clin. Microbiol. 41:2337-2340. (Pubitemid 36712433)
3. Baker CN, Banerjee SN, Tenover FC. 1994. Evaluation of Alamar colorimetric MIC method for antimicrobial susceptibility testing of gramnegative bacteria. J. Clin. Microbiol. 32:1261-1267. (Pubitemid 24132557)
4. Barton MD, Hughes KL. 1980. Corynebacterium equi: a review. 50:60-80.
5. Bell G, Gouyon PH. 2003. Arming the enemy: the evolution of resistance to self-proteins. Microbiology 149:1367-1375. (Pubitemid 36764061)
6. Bonapace CR, Bosso JA, Friedrich LV, White RL. 2002. Comparison of methods of interpretation of checkerboard synergy testing. Diagn. Microbiol. Infect. Dis. 44:363-366. (Pubitemid 36120715)
7. Boyen F, Pasmans F, Haesebrouck F. 2011. Acquired antimicrobial resistance in equine Rhodococcus equi isolates. Vet. Rec. 168:101.
8. Bruhn O, Grötzinger J, Cascorbi I, Jung S. 2011. Antimicrobial peptides and proteins of the horse - insights into a well-armed organism. Vet. Res. 42:98.
9. Bruhn O, et al. 2007. A novel horse alpha-defensin: gene transcription, recombinant expression and characterization of the structure and function. Biochem. J. 407:267-276. (Pubitemid 47556991)
10. Buckley T, McManamon E, Stanbridge S. 2007. Resistance studies of erythromycin and rifampin for Rhodococcus equi over a 10-year period. Irish Vet. J. 60:728-731. (Pubitemid 350255449)
11. Cassone M, Otvos L, Jr. 2010. Synergy among antibacterial peptides and between peptides and small-molecule antibiotics. Expert Rev. Anti Infect. Ther. 8:703-716.
12. CLSI. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-eighth edition, M07-A8. CLSI, Wayne, PA.
13. Cornish N, Washington JA. 1999. Rhodococcus equi infections: clinical features and laboratory diagnosis. Curr. Clin. Top. Infect. Dis. 19:198-215.
14. De Smet K, Contreras R. 2005. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol. Lett. 27:1337-1347. (Pubitemid 41805626)
15. Devi P, Malhotra S, Chadha A. 2011. Bacteremia due to Rhodococcus equi in an immunocompetent infant. Indian J. Med. Microbiol. 29:65-68.
16. Eliopoulos GM, Moellering RC. 1996. Antimicrobial combinations, p 330-396. In LorianV(ed), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, MD.
17. Giacometti A, Cirioni O, Barchiesi F, Fortuna M, Scalise G. 1999. In-vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 44:641-645. (Pubitemid 29532842)
18. Giacometti A, et al. 2005. In vitro activity of citropin 1.1 alone and in combination with clinically used antimicrobial agents against Rhodococcus equi. J. Antimicrob. Chemother. 56:410-412. (Pubitemid 41158535)
19. Giacometti A, et al. 2005. In vitro activity and killing effect of uperin 3.6 against gram-positive cocci isolated from immunocompromised patients. Antimicrob. Agents Chemother. 49:3933-3936. (Pubitemid 41233053)
20. Giguere S, et al. 2004. Retrospective comparison of azithromycin, clarithromycin, and erythromycin for the treatment of foals with Rhodococcus equi pneumonia. J. Vet. Intern. Med. 18:568-573. (Pubitemid 39107551)
21. Giguere S, Prescott JF. 1997. Clinical manifestations, diagnosis, treatment, and prevention of Rhodococcus equi infections in foals. Vet. Microbiol. 56:313-334. (Pubitemid 27339160)
22. Goldman MJ, et al. 1997. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88:553-560. (Pubitemid 27154420)
23. Golub B, Spink FGWW. 1967. Lung abscess due to Corynebacterium equi. Report of first human infection. Ann. Intern. Med. 66:1174-1177.
24. Harvey RL, Sunstrum JC. 1991. Rhodococcus equi infection in patients with and without human immunodeficiency virus infection. Rev. Infect. Dis. 13:139-145.
25. Hillidge CJ. 1987. Use of erythromycin-rifampin combination in treatment of Rhodococcus equi pneumonia. Vet. Microbiol. 14:337-342. (Pubitemid 18016066)
26. Jung S, et al. 2011. Human beta-defensin 2 and beta-defensin 3 chimeric peptides reveal the structural basis of the pathogen specificity of their parent molecules. Antimicrob. Agents Chemother. 55:954-960.
27. Kedlaya I, Ing MB, Wong SS. 2001. Rhodococcus equi infections in immunocompetent hosts: case report and review. Clin. Infect. Dis. 32: E39-E46.
28. Kenney DG, Robbins SC, Prescott JF, Kaushik A, Baird JD. 1994. Development of reactive arthritis and resistance to erythromycin and rifampin in a foal during treatment for Rhodococcus equi pneumonia. Equine Vet. J. 26:246-248.
29. Lavoie JP, Fiset L, Laverty S. 1994. Review of 40 cases of lung abscesses in foals and adult horses. Equine Vet. J. 26:348-352.
30. Marr AK, Gooderham WJ, Hancock RE. 2006. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr. Opin. Pharmacol. 6:468-472. (Pubitemid 44340665)
31. Mauger C. 2009. D.V.M. thesis. Retrospective study of equine rhodococcosis observed at autopsy on 1617 foals at the "LERPE" (AFSSA, Dozulé) from 1986 to 2006. Ecole Nationale Vétérinaire de Toulouse, Toulouse, France. (In French.)
32. Nizet V. 2006. Antimicrobial peptide resistance mechanisms of human bacterial pathogens. Curr. Issues Mol. Biol. 8:11-26. (Pubitemid 43141388)
33. Perron GG, Zasloff M, Bell G. 2006. Experimental evolution of resistance to an antimicrobial peptide. Proc. Biol. Sci. 273:251-256. (Pubitemid 46768100)
34. Pick U. 1981. Liposomes with a large trapping capacity prepared by freezing and thawing of sonicated phospholipid mixtures. Arch. Biochem. Biophys. 212:186-194.
35. Scocchi M, et al. 1999. Novel cathelicidins in horse leukocytes(1). FEBS Lett. 457:459-464.
36. Shin SY, et al. 2001. Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs. J. Pept. Res. 58:504-514. (Pubitemid 34169377)
37. Skerlavaj B, Scocchi M, Gennaro R, Risso A, Zanetti M. 2001. Structural and functional analysis of horse cathelicidin peptides. Antimicrob. Agents Chemother. 45:715-722. (Pubitemid 32182014)
38. Steinberg DA, et al. 1997. Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity. Antimicrob. Agents Chemother. 41: 1738-1742. (Pubitemid 27339878)
39. Sydor T, et al. 2008. A mycolyl transferase mutant of Rhodococcus equi lacking capsule integrity is fully virulent. Vet. Microbiol. 128:327-341. (Pubitemid 351305097)
40. Takai S, Sasaki Y, Tsubaki S. 1995. Rhodococcus equi infection in foals: current concepts and implication for future research. J. Equine Sci.6:105-119.
41. Topino S, Galati V, Grilli E, Petrosillo N. 2010. Rhodococcus equi infection in HIV-infected individuals: case reports and review of the literature. AIDS Patient Care STDS 24:211-222.
42. Travis SM, et al. 2000. Bactericidal activity of mammalian cathelicidin-derived peptides. Infect. Immun. 68:2748-2755. (Pubitemid 30253851)
43. Vaucher RA, da Motta Ade S, Brandelli A. 2010. Evaluation of the in vitro cytotoxicity of the antimicrobial peptide P34. Cell Biol. Int. 34:317-323.
44. Weinstock DM, Brown AE. 2002. Rhodococcus equi: an emerging pathogen. Clin. Infect. Dis. 34:1379-1385. (Pubitemid 34507948)
45. Yager JA. 1987. The pathogenesis of Rhodococcus equi pneumonia in foals. Vet. Microbiol. 14:225-232.
46. Yamshchikov AV, Schuetz A, Lyon GM. 2010. Rhodococcus equi infection. Lancet Infect. Dis. 10:350-359.
47. Zasloff M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395. (Pubitemid 34100944)
48. Zhang L, et al. 2005. Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrob. Agents Chemother. 49:2921-2927. (Pubitemid 40917611)
49. Zink MC, Yager JA, Smart NL. 1985. Corynebacterium equi infection in horses, 1958-1984: a review of 131 cases. Am. J. Vet. Res. 46:2171-2174.